Back to Peptide Encyclopedia
Growth Hormone SecretionApproved
Tesamorelin
Egrifta
GHRH analog specifically approved for reducing visceral adipose tissue.
Prescription3 protocols
Approved by FDA only — not in all jurisdictions
·Educational information. Not medical advice or a recommendation for use.Key Facts: Tesamorelin
Category
Growth Hormone Secretion
Evidence
Approved
Availability
Prescription
Protocols
3
Research Overview & Mechanisms
Stimulates GH release, targeting visceral fat.
Reported Research Benefits
Visceral fat reduction
GH stimulation
Available Protocols
Frequently Asked Questions
FAQ
GHRH analog specifically approved for reducing visceral adipose tissue.
Advanced Compound Intelligence
—
Human studies
—
Key studies
—
Interactions
Approved
Evidence tier
Verified intelligence
Research summaryClinical Evidence
Approved
View all studies on PubMedApproved by regulatory agencies (FDA/EMA) with extensive Phase III clinical trial data.
Scientific Sources & Further Reading
Explore peer-reviewed research about Tesamorelin:
External links open in new tabs. Always verify information with qualified healthcare providers.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →